HS-10542
Phase 2Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.HS-10542 is one of 61 small molecule programs targeting Paroxysmal Nocturnal Hemoglobinuria. It is currently in Phase 2.
2
Indications
3
Total Trials
3
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
99 competitors in Iga Nephropathy
#DrugCompanyPhaseTrials
1Avapro
SanofiPhase 3
Kerendia
BayerPhase 3
Farxiga
AstraZenecaPhase 3
Filspari
TTravere Therapeutics, Inc.
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
LNP023
NovartisPhase 3
Vanrafia
NovartisPhase 2
Telitacicept
VVor Biopharma
Phase 3
Mezagitamab
TakedaPhase 3
Atacicept
EMD SeronoPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HS-10542. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details